Alkermes ALKS 7290 shows positive Phase 1b ADHD data; AISRS cuts 14–19 pts

Alkermes plc.

ALKS 7290 (OX2R agonist) improved ADHD symptoms: median AISRS reductions of 14.0 (20 mg) and 19.0 (50 mg) at day 14.
CGI-S median reductions of 1.0 (20 mg) and 2.0 (50 mg) at day 14; shift from markedly/moderately ill to mildly ill.
Generally well tolerated; no serious TEAEs; most common mild events: insomnia, pollakiuria, dizziness, change in sustained attention.
Phase 2 study (NCT07755410) enrolling ~312 adults with ADHD; first dose Sept 2026; data expected 2027.
First orexin 2 receptor agonist to show clinically meaningful ADHD improvements; supports broader orexin portfolio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.